Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer-Reference-Cited by-同舟云学术

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

Published:2024-07 Issue:7 Volume:9 Page:103619
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Schettini F.,Nucera S.,Brasó-Maristany F.,De Santo I.,Pascual T.,Bergamino M.,Galván P.,Conte B.,Seguí E.,García Fructuoso I.,Gómez Bravo R.,Rivera P.,Rodríguez A.B.,Martínez-Sáez O.,Ganau S.,Sanfeliu E.,González-Farre B.,Vidal Losada M.J.,Adamo B.,Cebrecos I.,Mension E.,Oses G.,Jares P.,Vidal-Sicart S.,Mollà M.,Muñoz M.,Prat A.

Publisher

Elsevier BV

Reference39 articles.

1. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer;Falato;Cancer Treat Rev,2023

2. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011;Goldhirsch;Ann Oncol,2011

3. Neoadjuvant endocrine therapy for luminal breast tumors: state of the art, challenges and future perspectives;Sirico;Crit Rev Oncol Hematol,2023

4. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: which role for gene expression assays?;Garufi;Cancer Treat Rev,2022

5. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches;European Journal of Cancer;2024-09